Crinetics Pharmaceuticals (CRNX) Profit After Tax (2017 - 2026)

Crinetics Pharmaceuticals' Profit After Tax history runs 10 years deep, the most recent figure standing at -$127.8 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 12404.62% year-over-year to -$127.8 million; the TTM figure through Mar 2026 stood at -$258.6 million (down 73.55% YoY), while the FY2025 annual figure was $902000.0, up 6542.86% from the prior year.
• Profit After Tax for Q1 2026 stood at -$127.8 million, down from -$329000.0 in the prior quarter.
• The five-year high for Profit After Tax was $156.3 million in Q4 2023, with the low at -$130.1 million in Q3 2025.
• The 5-year median for Profit After Tax is -$46.0 million (2023), against an average of -$37.7 million.
• The sharpest annual moves came in 2023 and 2026: Profit After Tax surged 421.95% in 2023, then tumbled 12404.62% in 2026.
• Crinetics Pharmaceuticals' Profit After Tax stood at -$48.5 million in 2022, then soared by 421.95% to $156.3 million in 2023, then slumped by 100.69% to -$1.1 million in 2024, then jumped by 69.4% to -$329000.0 in 2025, then tumbled by 38758.66% to -$127.8 million in 2026.
• Business Quant data shows CRNX's Profit After Tax at -$127.8 million in Q1 2026, -$329000.0 in Q4 2025, and -$130.1 million in Q3 2025.